De Greef Kathleen, Rolfo Christian, Russo Antonio, Chapelle Thiery, Bronte Giuseppe, Passiglia Francesco, Coelho Andreia, Papadimitriou Konstantinos, Peeters Marc
Kathleen De Greef, Thiery Chapelle, Hepatobiliary, Transplant and endocrine surgery Department, Antwerp University Hospital, 2650 Edegem, Belgium.
World J Gastroenterol. 2016 Aug 28;22(32):7215-25. doi: 10.3748/wjg.v22.i32.7215.
Colorectal cancer (CRC) is one of the leading causes of cancer-related death. Surgery, radiotherapy and chemotherapy have been till now the main therapeutic strategies for disease control and improvement of the overall survival. Twenty-five per cent (25%) of CRC patients have clinically detectable liver metastases at the initial diagnosis and approximately 50% develop liver metastases during their disease course. Twenty-thirty per cent (20%-30%) are CRC patients with metastases confined to the liver. Some years ago various studies showed a curative potential for liver metastases resection. For this reason some authors proposed the conversion of unresectable liver metastases to resectable to achieve cure. Since those results were published, a lot of regimens have been studied for resectability potential. Better results could be obtained by the combination of chemotherapy with targeted drugs, such as anti-VEGF and anti-EGFR monoclonal antibodies. However an accurate selection for patients to treat with these regimens and to operate for liver metastases is mandatory to reduce the risk of complications. A multidisciplinary team approach represents the best way for a proper patient management. The team needs to include surgeons, oncologists, diagnostic and interventional radiologists with expertise in hepatobiliary disease, molecular pathologists, and clinical nurse specialists. This review summarizes the most important findings on surgery and systemic treatment of CRC-related liver metastases.
结直肠癌(CRC)是癌症相关死亡的主要原因之一。迄今为止,手术、放疗和化疗一直是控制疾病和提高总生存率的主要治疗策略。25%的CRC患者在初诊时临床上可检测到肝转移,约50%的患者在病程中会发生肝转移。20%-30%的CRC患者转移灶局限于肝脏。几年前,各种研究表明肝转移灶切除具有治愈潜力。因此,一些作者提出将不可切除的肝转移灶转化为可切除以实现治愈。自从这些结果发表以来,已经研究了许多用于提高可切除性潜力的方案。化疗与靶向药物(如抗VEGF和抗EGFR单克隆抗体)联合使用可获得更好的结果。然而,为了降低并发症风险,必须准确选择接受这些方案治疗并进行肝转移灶手术的患者。多学科团队方法是妥善管理患者的最佳方式。该团队需要包括外科医生、肿瘤学家、在肝胆疾病方面有专业知识的诊断和介入放射科医生、分子病理学家以及临床护士专家。本综述总结了CRC相关肝转移灶手术和全身治疗的最重要发现。